KalVista Pharmaceuticals (KALV) is scheduled to report Q4 earnings on March 20, 2026. Analysts estimate EPS of $-0.53 and quarterly revenue of $30.86M.

In the most recent quarter (Q3), KalVista Pharmaceuticals reported EPS of $-0.92, beating estimates of $-1.04 by 0.12%. Revenue came in at $13.69M, exceeding the estimate of $6.33M by 1.16%.

Over the last 4 quarters, KalVista Pharmaceuticals has averaged an EPS surprise of 0.11% and a revenue surprise of 0.81%.